FDA Clearance

Business

Korro Bio Unveils RNA-Editing Therapy KRRO-121, Aiming to Redefine Ammonia Control for Rare Metabolic and Liver Disorders

At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.

Business

Analysts Bullish on BeOne Medicines: Phase 3 Success Fuels $3.8B Revenue Forecast for 2025

Citizens reiterates a 'Market Outperform' rating and $396 price target for BeOne Medicines (ONC), driven by robust Phase 3 trial results in gastric cancer. The firm highlights the company's strong pipeline and cash position as key growth drivers.

Business

Argenx's Vyvgart Surges Past Sales Forecasts, Fueling Optimism for Autoimmune Portfolio

Biotech firm Argenx SE sees its flagship drug Vyvgart outperform sales expectations in myasthenia gravis and CIDP treatments, with analysts pointing to sustained growth and regulatory momentum as key drivers.

Business

ResMed Posts Strong Q2 Growth, Eyes GLP-1 Tailwind and AI-Driven Innovation

ResMed reports robust revenue and margin expansion in its fiscal Q2 2026, driven by strong device and mask sales. Management highlights strategic investments in AI-powered patient tools and views GLP-1 medications as a potential catalyst for future demand.

Business

Altria Navigates Smoke-Free Shift Amid Illicit Vape Headwinds, Posts Steady Growth

Altria Group reported adjusted earnings growth and robust shareholder returns for 2025, even as it grapples with a rapidly transforming nicotine market dominated by illicit flavored vapes and intense competition in oral tobacco.

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Business

Saks OFF 5TH Slashes Store Footprint, Closing Dozens of Outlets in Bankruptcy Restructuring

Saks Global, the parent of luxury retailers Saks Fifth Avenue and Neiman Marcus, will shutter the vast majority of its Saks OFF 5TH off-price stores and all Last Call locations, marking a dramatic retreat from the discount luxury sector as it navigates Chapter 11.